INS and type 2 diabetes mellitus: Other human clinical studies aiming to evaluate the efficacy and safety G. lucidum in patients with confirmed type 2 diabetes with intervention lengths of 4–12 weeks have reported improvements in glycosylated haemoglobin (HbA1c), fasting plasma glucose, postprandial glucose, insulin, and C-peptide [94], whilst other studies have reported no changes in glucose parameters [95,96].